Asunto(s)
Detección Precoz del Cáncer/estadística & datos numéricos , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/epidemiología , Tomografía Computarizada por Rayos X/estadística & datos numéricos , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Neumología/normas , Medición de Riesgo , Fumar , Reino Unido/epidemiologíaAsunto(s)
Anticoagulantes/uso terapéutico , Dalteparina/uso terapéutico , Heparina/uso terapéutico , Embolia Pulmonar/prevención & control , Proyectos de Investigación , Trombosis de la Vena/prevención & control , Enfermedad Crítica/terapia , Humanos , Incidencia , Evaluación de Resultado en la Atención de Salud/métodosAsunto(s)
Amiloidosis/diagnóstico , Tos/etiología , Disnea Paroxística/etiología , Amiloidosis/tratamiento farmacológico , Amiloidosis/patología , Ingestión de Alimentos , Esófago/patología , Resultado Fatal , Humanos , Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas , Masculino , Persona de Mediana Edad , Miocardio/patología , Fonación , Inhibidores de la Bomba de Protones/uso terapéuticoRESUMEN
INTRODUCTION: The histological subtyping of non small cell lung cancer (NSCLC) is important in the selection of the optimal treatment for patients with advanced disease. There are now important differences in the chemotherapy regimens used for squamous and non-squamous cancers. Non-squamous cancers (particularly adenocarcinomas) are also suitable for targeted therapy if the epidermal growth factor receptor (EGFR) genetic mutation is present. Diagnosis is frequently made by fine needle aspiration from lymph node metastases. We have evaluated the adequacy of material obtained by EBUS-TBNA for subtyping of NSCLC. METHODS: All EBUS-TBNA procedures performed at Leeds Teaching Hospitals between February 2009 and November 2011 were analysed. Data was collected on the indication, final cytological diagnosis and whether EGFR mutation testing was possible. We analysed the data to establish our rate of NSCLC-NOS diagnoses and to determine the technical success of EGFR testing. RESULTS: Data from 391 procedures was analysed. The indication was staging of malignancy in 345 patients and suspected non-malignant disease in 48 patients. Malignant disease was diagnosed in 204 patients (53.7%), small cell 43, squamous cell 64, adenocarcinoma 40, adenosquamous 2, large cell 12, NSCLC-NOS 31 and malignant disease of non-lung primary 12. EBUS-TBNA identified 149 patients with NCSLC. Subtyping could be obtained in 118 (79.2%). The number of patients with a diagnosis of NSCLC NOS on EBUS-TBNA was 31 (20.8%, 95% CI 15-28%). Of the 204 specimens with a malignant diagnosis immunohistochemistry was performed in 149 (73.0%). It was not performed in 52 (25.5%) cases and there was insufficient material available in 3 (1.5%) cases. EGFR testing was requested in 36 patients. Our test success rate for EGFR mutation testing on EBUS-TBNA samples was 88.8% (95%CI 74.7-95.6%). CONCLUSION: EBUS-TBNA samples when made into cell blocks and subjected to a panel of immunohistochemical stains returned adequate tissue for cytological analysis in over 97% of cases, with an NOS rate of 20.8%. We have also shown that cytology specimens are adequate for EGFR mutation testing in over 88% of cases. We conclude that EBUS-TBNA is an accurate diagnostic test both for determining NSCLC subtype and performing EGFR mutation analysis to tailor treatment in lung cancer patients.